Evidence map›Paper›PMID 41415462›Full record

ArticlebioRxiv : the preprint server for biology2025

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Francesco Maura, Ciara L Freeman, Kylee H Maclachlan, Marta Larrayoz Ilundain, Bachisio Ziccheddu, Erin W Meermeier, Juan-Jose Garces, Michael Durante, Holly Lee, Ross Firestone and 36 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors.

Francesco MauraMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ciara L FreemanMoffitt Cancer Center, Tampa, FL, USA.
Kylee H MaclachlanMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marta Larrayoz IlundainDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, IDISNA, CIBERONC, University of Navarra, Pamplona, Spain.ORCID 0000-0001-6097-8244
Bachisio ZicchedduMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Erin W MeermeierMayo Clinic, Scottsdale, AZ, USA.
Juan-Jose GarcesMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael DuranteMyeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.ORCID 0000-0003-3137-6847
Holly LeeArnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Ross FirestoneMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Meghan MengesMoffitt Cancer Center, Tampa, FL, USA.
Kayla ReidMoffitt Cancer Center, Tampa, FL, USA.
Benjamin DiamondMyeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Marios PapadimitriouMyeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Ariosto Siqueira SilvaMoffitt Cancer Center, Tampa, FL, USA.
Praneeth Reddy SudalaguntaMoffitt Cancer Center, Tampa, FL, USA.
Noemie LeblayArnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Sungwoo AhnArnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Ethan FullerDana Farber Cancer Institute, Boston, USA.
Edward BriercheckDana Farber Cancer Institute, Boston, USA.
Meaghen E SharikMayo Clinic, Scottsdale, AZ, USA.
Megan T DuMayo Clinic, Scottsdale, AZ, USA.
Phaedra AgiusMoffitt Cancer Center, Tampa, FL, USA.
Doris K HansenMoffitt Cancer Center, Tampa, FL, USA.
Xiaofei SongMoffitt Cancer Center, Tampa, FL, USA.
Xiaohong ZhaoMoffitt Cancer Center, Tampa, FL, USA.
Mark B MeadsMoffitt Cancer Center, Tampa, FL, USA.
Jamie TeerMoffitt Cancer Center, Tampa, FL, USA.
Tomas JelinekDepartment of Haemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Patrick HagnerMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rachid BazExecutive Director, Translational Development, Bristol-Myers Squibb, Summit, NJ 07901.
Melissa AlsinaMoffitt Cancer Center, Tampa, FL, USA.
Anusuya M RamasubramanianArnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Eric SmithDana Farber Cancer Institute, Boston, USA.
Sergio A GiraltMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sham MailankodyMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Leif P BergsagelMayo Clinic, Scottsdale, AZ, USA.ORCID 0000-0003-1523-7388
Paola NeriArnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Marta ChesiMayo Clinic, Scottsdale, AZ, USA.
Jose A Martinez-ClimentDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, IDISNA, CIBERONC, University of Navarra, Pamplona, Spain.
Frederick L LockeMoffitt Cancer Center, Tampa, FL, USA.
Nizar J BahlisArnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Ola LandgrenMyeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.ORCID 0000-0001-6485-4839
Issam HamadehMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Saad Z UsmaniMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenneth H ShainMoffitt Cancer Center, Tampa, FL, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026
$24.1M
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled ComparisonR01CA244328 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI HEATHER S.L. JIM, Frederick Locke · 2022 to 2026
$3.8M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA240139NCI NIH HHS R01 CA244328
6 · The paper itself

Abstract

Chimeric antigen receptor T-cell (CART) and T-cell engager (TCE) therapies targeting B-cell maturation antigen (BCMA) are transforming the treatment landscape for relapsed multiple myeloma (MM). However, despite impressive initial response rates, most patients eventually relapse. To investigate this unmet medical need, we applied whole-genome sequencing (WGS) to MM cells from cohorts of 102 relapsed patients treated with anti-BCMA CART and TCE therapies. Several genomic alterations were associated with clinical outcomes, particularly primary refractoriness, including high genomic complexity and mutations in genes regulating plasma cell identity, which predicted resistance to therapy. Single-cell RNA sequencing further revealed that MM cells from refractory patients exhibited high proliferation signatures and reduced expression of

Identifiers

PMID41415462
PMCPMC12710967

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.